GCM
FLGT icon

Gladius Capital Management’s Fulgent Genetics FLGT Stock Holding History

Gladius Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,746
Closed -$81.4K – 136
2024
Q3 		$81.4K Buy
+3,746
New +$83.8K 0.01% 134
2024
Q2 		– Sell
-1,699
Closed -$36.9K – 326
2024
Q1 		$36.9K Buy
+1,699
New +$42.2K 0.01% 241

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gladius Capital Management's FLGT Position: Q4 2024 in Review

Gladius Capital Management sold out of Fulgent Genetics (FLGT) in Q4 2024, closing a stake of 3,746 shares — an estimated $81.4K sold.

Gladius Capital Management first reported a position in FLGT in Q1 2024 and held it in 2 quarters. The position peaked at $81.4K in Q3 2024. 189 funds tracked by Wall St. Rank hold FLGT as of Q4 2024.

  • Gladius Capital Management reported no remaining Fulgent Genetics position as of Q4 2024 after selling out during the quarter.
  • Gladius Capital Management sold 3,746 Fulgent Genetics shares in Q4 2024, an estimated $81.4K.
  • Gladius Capital Management first reported a position in Fulgent Genetics in Q1 2024 and held it in 2 quarters.
  • Gladius Capital Management's Fulgent Genetics position peaked at $81.4K in Q3 2024.
  • 189 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2024.

Based on Gladius Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.